Artigos com autorizações de acesso público - Alfredo FalconeSaiba mais
3 artigos não disponíveis publicamente
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
M Del Re, E Vasile, A Falcone, R Danesi, I Petrini
Expert review of molecular diagnostics 14 (4), 453-468, 2014
Autorizações: Government of Italy
Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer
M Suenaga, M Schirripa, S Cao, W Zhang, C Cremolini, S Lonardi, ...
The pharmacogenomics journal 21 (3), 285-295, 2021
Autorizações: US National Institutes of Health, Swiss Cancer League
BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases
R Moretto, C Cremolini, A Falcone
JAMA surgery 153 (12), 1162-1163, 2018
Autorizações: US National Institutes of Health
79 artigos disponíveis publicamente
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ...
Annals of Oncology 27 (8), 1386-1422, 2016
Autorizações: Cancer Research UK, National Institute for Health Research, UK
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795-801, 2015
Autorizações: US National Institutes of Health, Government of Spain, Government of Italy
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
Autorizações: UK Medical Research Council, National Institute for Health Research, UK
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the …
J Franko, Q Shi, JP Meyers, TS Maughan, RA Adams, MT Seymour, ...
The Lancet Oncology 17 (12), 1709-1719, 2016
Autorizações: Cancer Research UK
Primary tumor location as a prognostic factor in metastatic colorectal cancer
F Loupakis, D Yang, L Yau, S Feng, C Cremolini, W Zhang, MKH Maus, ...
Journal of the National Cancer Institute 107 (3), dju427, 2015
Autorizações: US National Institutes of Health
Quantitative evidence for early metastatic seeding in colorectal cancer
Z Hu, J Ding, Z Ma, R Sun, JA Seoane, J Scott Shaffer, CJ Suarez, ...
Nature genetics 51 (7), 1113-1122, 2019
Autorizações: US National Institutes of Health
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a …
J Tabernero, HJ Lenz, S Siena, A Sobrero, A Falcone, M Ychou, ...
The Lancet Oncology 16 (8), 937-948, 2015
Autorizações: US National Institutes of Health
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised …
CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ...
The Lancet Oncology 20 (3), 420-435, 2019
Autorizações: German Research Foundation
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
F Loupakis, C Cremolini, L Salvatore, G Masi, E Sensi, M Schirripa, ...
European journal of cancer 50 (1), 57-63, 2014
Autorizações: US National Institutes of Health
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ...
Journal of the National Cancer Institute 109 (12), djx089, 2017
Autorizações: Government of Italy
Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database
LA Renfro, F Loupakis, RA Adams, MT Seymour, V Heinemann, ...
Journal of Clinical Oncology 34 (2), 144-150, 2016
Autorizações: US National Institutes of Health, Cancer Research UK
Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial
E Martinelli, G Martini, V Famiglietti, T Troiani, S Napolitano, ...
JAMA oncology 7 (10), 1529-1535, 2021
Autorizações: Government of Italy
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials …
Q Shi, A De Gramont, A Grothey, J Zalcberg, B Chibaudel, HJ Schmoll, ...
Journal of Clinical Oncology 33 (1), 22-28, 2015
Autorizações: US National Institutes of Health, Cancer Research UK
Personalizing survival predictions in advanced colorectal cancer: the ARCAD nomogram project
KM Sjoquist, LA Renfro, RJ Simes, NC Tebbutt, S Clarke, MT Seymour, ...
JNCI: Journal of the National Cancer Institute 110 (6), 638-648, 2018
Autorizações: US National Institutes of Health, National Health and Medical Research …
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, F Morano, G Fucà, ...
Annals of Oncology 29 (6), 1394-1401, 2018
Autorizações: Government of Italy
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
C Caparello, LL Meijer, I Garajova, A Falcone, TY Le Large, N Funel, ...
World journal of gastroenterology 22 (31), 6987, 2016
Autorizações: Government of Italy
Contribution of KRAS mutations and c. 2369C> T (p. T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
M Del Re, M Tiseo, P Bordi, A D'Incecco, A Camerini, I Petrini, M Lucchesi, ...
Oncotarget 8 (8), 13611, 2017
Autorizações: Government of Italy
As informações de publicação e financiamento são determinadas automaticamente por um programa de computador